Livforsakringsbolaget Skandia Omsesidigt Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6,925.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,100 shares of the biotechnology company's stock after buying an additional 27,700 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt owned 0.06% of United Therapeutics worth $9,904,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. World Investment Advisors LLC acquired a new stake in shares of United Therapeutics in the third quarter valued at about $139,206,000. FMR LLC increased its holdings in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after buying an additional 314,004 shares in the last quarter. Assetmark Inc. lifted its position in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after acquiring an additional 152,249 shares during the period. Franklin Resources Inc. boosted its stake in shares of United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after acquiring an additional 123,929 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of United Therapeutics by 32.5% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company's stock worth $123,181,000 after acquiring an additional 84,369 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity

In related news, Director Nilda Mesa sold 255 shares of the company's stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 121,864 shares of company stock valued at $44,516,965 over the last quarter. Company insiders own 11.90% of the company's stock.

United Therapeutics Price Performance

UTHR traded up $7.67 during trading on Tuesday, hitting $353.31. The company's stock had a trading volume of 508,279 shares, compared to its average volume of 319,429. United Therapeutics Co. has a twelve month low of $210.64 and a twelve month high of $417.82. The stock has a market cap of $15.78 billion, a PE ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57. The firm's 50 day moving average price is $362.06 and its 200-day moving average price is $358.24.

Analyst Ratings Changes

Several brokerages recently issued reports on UTHR. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. TD Cowen lifted their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, January 16th. UBS Group lifted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, Argus increased their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $382.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.